Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

Trial Profile

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Catridecacog (Primary)
  • Indications Factor XIII deficiency
  • Focus Adverse reactions
  • Acronyms mentor™6
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Apr 2015 Status changed from not stated to recruiting.
    • 29 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top